Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

29.47 -0.87 (-2.87%)
Streaming Delayed Price Updated: 2:23 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Dow Jones Hits Record as Shutdown Deal Nears—AI Sector Feels the Heat ↗
Optimism about a possible end to the U.S. government shutdown pushed the Dow Jones to new highs, but Big Tech couldn’t keep up. Nvidia took a beating after SoftBank’s surprise exit. 
Via Chartmill
Topics Stocks
News headline image
uniQure (QURE) Q3 2025 Earnings Call Transcript ↗
uniQure (QURE) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse of uniQure's Earnings Potential ↗
 
Via Benzinga
uniQure Stock Tumbled 56% Today: What’s The FDA Angle? ↗
Via Stocktwits
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection ↗
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade. 
Via Benzinga
News headline image
Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug ↗
The company was nearing approval for a treatment for a rare, neurodegenerative disease. Then, the FDA spoke. 
Via Investor's Business Daily
Topics Earnings
News headline image
Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline. 
Via Benzinga
News headline image
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Which stocks are moving on Monday? ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Gold Edges Higher; ISM Manufacturing PMI Falls In October ↗
 
Via Benzinga
News headline image
UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data ↗
UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans. 
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Nasdaq Surges 1%; ON Semiconductor Posts Upbeat Q3 Earnings ↗
 
Via Benzinga
News headline image
Uniqure Plummets 59% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy ↗
An analyst described the FDA feedback as "confusing" and "unexpected" for the experimental Huntington's disease treatment. 
Via Investor's Business Daily
News headline image
Discover the top movers in Monday's pre-market session. ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Breakout Momentum Plays You Need to Know About ↗
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential. 
Via MarketBeat
News headline image
Why Is Protalix BioTherapeutics Stock Falling On Friday? ↗
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.